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Background: Since multiple lung cancer treatment strategies differ, it is essential for 
clinicians to be able to distinguish between separate primary lesions and metastasis. In the 
present study, we used array comparative genomic hybridization (aCGH) and somatic 
mutation (epidermal growth factor receptor: EGFR) to analyze genomic alteration profiles 
in lung cancer patients. To validate the consistency among the pathological assessments 35 
and clarify the clinical differences between double primary lesions and metastasis, we also 
examined synchronous double lung cancer clinical data. Methods: Between January 1970 
and March 2010, 2215 patients with lung cancer underwent surgical resection at Nagasaki 
University Hospital. We performed molecular analysis of 12 synchronous double lung 
cancer patients without lymph node metastasis (intrapulmonary metastasis in the same 40 
lobe (pm1): n=6, primary: n=6). We then evaluated the clinical outcomes of patients with 
pathologically diagnosed synchronous double lung cancers (intrapulmonary metastasis 
(pm): n=80, primary: n=39) and other T3 tumors (n=230). Results: Examination of the 
concordance rate (CR) of the copy number changes (CNCs) for paired tumors showed that 
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the metastasis group was larger than the primary group (55.5% vs. 19.6%, p=0.04). 45 
Pathological diagnosis and molecular classification were the same in 10 out of 12 cases 
(83%). As compared to the primary group, there tended to be an inferior 5-year survival 
curve for the pm group. However, in N0 patients, the survival curve for the pm group 
overlapped the primary group, while the survival rate of the pm1 group was much higher 
than that of other T3 group (p<0.01). Conclusions: Both pathological and molecular 50 
assessment using aCGH adapted in the current study appeared to have a consistency. 
Pathological pm1(T3)N0 patients may have a better prognosis than other T3N0 patients. 
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With the development of higher-resolution chest imaging techniques over the past 
decade, there has been a rising number of multiple lung cancer patients that are being 65 
diagnosed [1]. The crucial issue regarding multiple lung cancers is whether they represent 
separate primary lesions or metastasis, as this affects both the stage assessment and the 
planning of subsequent treatments. If paired tumors are diagnosed as primary lesions, the 
main treatment will be surgery, as these are considered to be a local disease. However, 
when metastasis is found in these patients, they are automatically classified as T3, for 70 
which surgery and additional chemoradiotherapy will be performed due to this being a 
systemic disease. 
The clinical and pathological criteria used to define multiple primary lung tumors were 
initially published by Martini and Melamed in 1975 [2]. These criteria are based on tumor 
locations and histological findings. However, clinicians empirically know that some cases 75 
do not completely meet the criteria. For example, metastasis is defined as having multiple 
tumors within the same segment that are histologically similar. However multiple 
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squamous cell carcinomas in the fibrotic lung sometimes arise within the same area. In 
addition, bronchioloalveolar carcinomas often show multiple ground-glass attenuation 
within the same segments and thus, these are commonly defined as multiple primary lung 80 
cancers. 
Since the 1970s, a variety of reliable and powerful molecular tools, such as 
immunohistochemical and molecular analysis, have become available for evaluating 
clonal relationships between multiple tumors [3-6]. Mutational analysis of epidermal 
growth factor receptor (EGFR) and Kirsten rat sarcoma 2 viral oncogene homolog 85 
(KRAS) mutation [7] have proven to be powerful tools that can be used in differentiating 
double primary lung adenocarcinoma from metastatic lesions. Genomic DNA copy 
number alterations have also been shown to be key genetic events in the development and 
progression of human cancers and therefore, array comparative genomic hybridization 
(aCGH) can be utilized during diagnostic procedures [8,9]. When the fluorescence ratio of 90 
the aCGH test along with the reference hybridization signals are compared to the reference 
diploid genome, this yields information on the relative copy number of the sequences in 
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the test genome. A series of aCGH studies have examined various organs, with special 
focus on breast tumors [10-15]. Results have demonstrated that this is a powerful method 
for undertaking comprehensive genome-wide searches, in addition to being an attractive 95 
strategy that can be used to define true recurrences among multiple tumors [5, 16]. 
Nonetheless, there have been few studies specifically designed to examine use of this 
aCGH technology in lung cancers [17].  
In the new 7th TNM staging system guideline (Union of International Cancer Control: 
UICC. Ver. 7) [18], pm1 was downgraded from T4 to T3, while metastasis in other lobes 100 
on the same side (pm2) was downgraded from M1 to T4. Therefore, this new TNM 
staging system could potentially lead to changes in multiple lung cancer patient prognosis. 
To validate clinicopathological assessment and clarify the difference between double 
primary lesions and pulmonary metastasis, we analyzed genomic profiles of 12 cases that 
were clinicopathologically defined as double primary lesions (n=6) or metastasis (n=6). To 105 
exclude the impact of the major prognostic factor of lymph node metastasis, we focused 
on pathological N0 patients and analyzed clinical data from postoperative synchronous 
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double lung cancer patients. 
 
Materials and Methods 110 
Patients  
Between January 1970 and March 2010, a series of 2215 patients with lung cancer 
underwent surgical resection at Nagasaki University Hospital. A total of 119 patients 
(5.8%) had synchronous double lesions, with 80 diagnosed as intrapulmonary metastatic 
NSCLC (pm) and 39 as double primary NSCLC (primary). Out of 119 patients, 66 were 115 
classified as N0, with 28 having double primary and 38 having pm. As per the 7th TNM 
classification guideline, 145 patients met the T3N0 criteria, including 32 who were 
classified as pm1N0. Table 1 shows the clinical characteristics for the 12 patients (24 
tumor samples) examined for the genomic and mutation profiling. 
 120 
Pathological Evaluation 
Samples classified as“primary”had to 1) have a different histological subtype, 2) be 
different or exhibit clear differentiation in paired tumors, 3) have undergone different 
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immunostaining experiments, for example thyroid transcription factor 1 (TTF-1), 
cytokeratins 7 (CK7), and 20 (CK20), or 4) have low grade lymphatic and blood vessel 125 
invasion. All of the pathological materials available for tumor classification were reviewed 
by three expert pathologists using the standard World Health Organization Classifications 
[19]. Disease status was staged according to the TNM staging system (UICC Ver. 7). 
Tumor locations were used as supportive information. 
 130 
Tissue Procurement 
All patients provided informed consent for the use of tumor specimens, and the Ethics 
Review Board on Clinical Research of Nagasaki University Hospital approved the study 
protocol (#10072868). Tumor specimens were obtained from patients with lung cancer 
who underwent surgical resection at Nagasaki University Hospital from January 1970 to 135 
March 2010. Among the patients having their synchronous double lung cancer resected 
operatively, cases in which the tumor specimen contained more than 70% cancer cells 
were saved for further molecular examinations. A total of 12 cases with 24 tumors were 
included in the study. At the time of the surgeries, study patients were considered to have 
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clinicopathological findings of either double “primaries” or “pm”. DNA was extracted 140 
from formalin-fixed, paraffin-embedded block tissue using the QIAamp DNA Mini Kit 
(Qiagen, Germany) in accordance with the previously reported manufacturer’s protocol 
[20]. The detailed method is described in Supplemental Text I.  
 
Genomic Profiling 145 
Genomic DNA extracted from samples and the reference female genomic DNA 
(Promega, Madison, WI, USA) were chemically labeled with Cy5 and Cy3, respectively, 
using the Genomic DNA ULS Labeling Kit (Agilent Technologies, USA) and hybridized 
to Agilent 60K comparative genomic hybridization arrays according to the manufacturer’s 
instructions. Images of microarrays were scanned by an Agilent DNA Microarray Scanner, 150 
and raw microarray image files were generated using the Feature Extraction Software 
(version 9.5). Agilent Genomic Workbench (version 5.0) was used to visualize, detect and 
analyze chromosomal changes, with the ADM-2 algorithm threshold set to 5.0. We defined 
a log2 ratio more than 0.25 as a gain, and less than -0.25 as a loss. The total length of the 
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chromosomal aberrant region, which is the sum of each segment gained or lost, was used 155 
as an indicator of genomic instability. 
The patterns of gains and losses for each pair of tumors were compared. Since the 
concordance of the copy number changes (CNCs) between each of the paired tumors have 
been used as diagnostic values in several previous studies [8,10,21], we used these to 
clarify whether cases were primary or metastasis. The concordance rate (CR) was defined 160 
as the ratio of the length of the chromosomal aberrant region between two tumors, which 
was essentially a modified value of measure M that was derived from a percent 
concordance calculation by Waldman et al. [10,22]. This value was the percentage of the 
length of overlapping CNCs divided by the average length of the CNCs for each pair of 
tumors. For an (i,j) pair, this would be calculated as follows: 165 
 ×100, 
in which Li and Lj are the length of the chromosomal aberrant region of the (i,j) pair.  
The mean CR for all pairs of tumors that came from different patients in this study, 
and which therefore were definitively independent, was 11.4% (range, 0.001% to 
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75.76%). Supplemental Figure I shows the histogram that was created using the data. We 170 
defined 50% as a criterion of diagnosis since 52% was the border range within the upper 
95% of this histogram. Tumor pairs were classified as metastasis when the rate exceeded 
the criterion.  
 
Mutational Profiling 175 
The hot-spot mutations of EGFR, along with the 9- to 18-bp deletions in exon 19 and 
the L858R missense mutation in exon 21 were analyzed using the mutant-enriched 
polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) 
method [23]. Primer pairs used for PCR in this study are shown in Table 2, with the 
detailed method described in Supplemental Text II.  180 
 
Statistical Analysis 
Overall survival (OS) and Disease free survival (DFS) was assessed using the 
Kaplan-Meier method. The influence of classifications was studied using the log-rank test. 
Comparisons of results were examined using the Mann-Whitney U test, Kruskal-Wallis 185 
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test, Welch`s t test, and χ2 test. Results were considered significant at the 0.05 level. SPSS 




Molecular Analysis Performed by Array CGH and Mutational Profiling of EGFR 
To evaluate the pathological diagnoses as double primary or metastasis, we conducted 
aCGH analyses on the 24 tumor pairs from the 12 cases in the N0 group. Both double 
primary (n=6) and metastatic (n=6) cancers were observed. The aCGH genomic profiles 
for each of 12 cases are shown in Supplemental Figure II. Figure 1 shows a typical 195 
aCGH result. Amplification regions were noted in both tumors in case 2, while case 7 
displayed amplification in one of the tumors on 5p. The paired tumors seen in case 2 
exhibited similar genomic alterations, which suggest a diagnosis of metastasis. However, 
the different alterations seen in case 7 suggest a diagnosis of double primary. 
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We calculated the total number and size of the CNCs along with the CR between each 200 
pair of tumors. Cases pathologically diagnosed as metastasis exhibited a statistically 
higher CR as compared to that seen in the double primary groups (55.5% vs. 19.6%, 
p=0.04). Using the results of aCGH, we cytogenetically diagnosed the 12 cases as either 
double primary or metastases. A total of 6 patients were diagnosed as double primary 
while the other 6 were metastasis (Table 3).  205 
We also performed hot-spot mutation analysis of EGFR and detected mutations of 
either exon 19 or 21 in 8 out of the 12 cases (66.7%). A previous study found that double 
primary cancer occurred when there were different mutations between the paired tumors, 
while metastasis occurred in cases with the same mutation [7]. Based on these findings, 
the mutation analysis in the current study indicated that 4 cases were double primary 210 
cancers, 4 were metastasis, and 4 were equivocal (Table 3). Results for 7 out of 12 of 
these cases (58.3%) were identical to those of the pathological examinations. 
 
Comparison of Pathology and Molecular Profiling 
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Table 3 summarizes the results for the classification schemes. While the aCGH and 215 
mutational analysis results were comparable, the molecular diagnosis had to be determined 
using the results of aCGH, as the mutational analysis was ambiguous. Molecular diagnosis 
classified 6 cases as double primary and 6 cases as metastasis. The overlap between the 
pathological diagnosis and the molecular classification was 83% (10/12 cases), with a 
statistically strong correlation noted between the two (p=0.04). There were 2 contradicted 220 
cases (cases 1 and 11). Because of a similar histology with the well-differentiated 
papillary type, the pathological diagnosis for case 1 was pm1. However the CR was only 
2.6%. Since detailed pathology for case 1 indicated the primary and secondary lesion 
tumor sizes were 20 and 12 mm without lymphatic and blood vessel invasion, we 
considered this case to be double primary. Case 11 was also double primary, as it had a 225 
lesion with a mucinous component in the papillary background, along with another lesion 
that showed a mucinous invasive adenocarcinoma with a small moderately differentiated 
component. However, since the CR was high (68.8%) in this case, there is a possibility 
that the mucinous component might have metastasized from the original lesion.  





 Comparisons of the pathologically diagnosed double primary and intrapulmonary 
metastatic groups indicated the intrapulmonary metastasis cases had a significantly larger 
tumor size (p=0.04), higher frequencies of lymph node metastasis (p<0.01) and pleural 
invasion (p=0.02). In addition, most of the intrapulmonary metastasis was observed in the 235 
same lobe (p<0.01). In the double primary group, smoking was more frequently observed 
as compared to the metastasis group (p=0.04) (data not shown). When N0 patients were 
compared, only the location proved to be a significantly different clinical factor. 
Furthermore, double primary lesions were often observed in a different lobe while 
intrapulmonary metastasis was usually observed in the same lobe (p<0.01) (Table 4). 240 
 
Survival Curves for the Double Primary and Metastasis Groups 
Metastasis patients tended to have an inferior overall 5-year survival curve as 
compared to the double primary group (p=0.26) (Fig. 2a). However, when focusing on the 
 Arai J. et al. 
18 
 
pm1N0 patients, the patient OS and DFS curves for pm1 and double primary cancers 245 
crossed, with the 5-year OS higher than 68% in both groups (p=0.14, 0.93) (Fig. 2b,c). It 
was also notable that the 5-year OS rates for pm1N0 patients were extremely higher than 
the rates seen for the other T3 patients (p<0.01) (Fig. 2d). 
 
Discussion 250 
To evaluate the accuracy of pathological diagnoses, we performed an aCGH analysis 
and then determined the cytogenetic and mutational profiles of synchronous double 
NSCLC. Notably, our results showed the CR of the CNCs of the paired tumors in the 
pathological pm1 group were significantly higher than that seen for the pathological 
double primary group. This suggests primary tumors are a molecularly different neoplasm. 255 
With regard to the diagnosis, 10 out of 12 (83%) patients had the same molecular and 
pathological diagnosis, which is comparable to a previously published study [24]. 
Although there were 2 cases with conflicting diagnoses (cases 1 and 11), the detailed 
pathological analyses supported the aCGH results. Pathological diagnoses are based on 
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subjective assessments. In contrast, the cytogenetic profiles were calculated using an 260 
aCGH analysis, which objectively attempts to determine whether the tumors are 
monoclonal or not [9-16]. Therefore, we assume the aCGH analysis should exhibit less 
variance and provide superior pathological results in these limited difficult cases. 
Girard et al., however, has reported there are several drawbacks to using aCGH in 
normal clinical practices. First, the procedure requires fresh frozen tissue and large 265 
amounts of genomic DNA. In the present study, we demonstrated that formalin-fixed, 
paraffin-embedded tissues can be used in aCGH studies, which improves the tissue 
handling aspect. Second, aCGH is still expensive and can be both a time-consuming and 
labor-intensive procedure. Therefore, although the aCGH analytical results appear to be 
preferable to the pathological diagnostic results, the pathological diagnostic workup 270 
remains the first-line tool for differentiating between double primary and pm in the 
clinical practice.  
With regard to mutational profiling, there may be several limitations. In a case with 
two tumors having matched EGFR mutations, we assume the tumors are metastasis 
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because theoretically metastatic lesions inherit genomic characteristics in theory. 275 
However, it has been previously suggested that matched mutations may occur in double 
primary while additional mutations may occur in metastasis [25]. Additionally, several 
studies have reported finding intratumor heterogeneity of the EGFR mutation [17, 26-28]. 
Moreover, since 4 out of the 12 paired tumors harbored no mutations in either tumor, it 
was impossible to determine the clonal relationships. Because of this, we were only able to 280 
diagnose 1 out of 12 cases as being irrefutable double primary in the present study (case 
12, Table 2). These previous findings are in line with the ambiguity of the mutational 
analysis. Thus, as has been previously suggested, utilization of a specific molecular 
alteration, which includes KRAS, P53, and EML4-ALK, is required to make a more 
precise diagnosis [21]. 285 
We have shown that the 5-year survival rates for synchronous double primary and 
intrapulmonary metastasis patients are similar in the N0 patients, although the theoretical 
prognosis of pm1 patients appears to be poorer than that for the double primary patients 
because pm1 is classified as T3 and most of the double primary in the present study was 
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classified as T1 (Table 1). Additionally, the pm1 5-year survival rates in N0 patients were 290 
much better than the rates found for other T3 patients. Because of the unexpectedly 
favorable prognosis found for the pm1n0 patients, we decided to reanalyze the survival 
data based on the definition of Martini and Melamed. In addition, we also reexamined the 
data via the comprehensive histologic subtyping assessment methodology, which has been 
reported by Travis et al. to be a very accurate histological analysis for multiple lung 295 
adenocarcinoma diagnosis [29]. While our reanalysis found that the diagnosis changed in 
5 out of 119 cases, the results of the overall survival and disease free survival curves 
remained similar (data not shown). Therefore, we can conclude that our survival data was 
reliable. Theoretically, intrapulmonary metastasis can occur at the micro lymphatic or 
blood vessel implantation before hilar lymph node metastasis. In such cases, single 300 
lobectomy might be sufficient for the purpose of complete resection. Detailed analyses of 
the clinicopathological data of the 32 pm1N0 patients showed that with the exception of 
one patient, all of the metastatic tumor diameters were less than 3 cm. Therefore, we 
postulate that most of the small-sized pm1N0, especially those less than 3 cm, could have 
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remained to some extent within the lung, thereby leading to an undue influence on the 305 
diagnosis. Specific information on the T grade of the small-sized pm1N0 might ultimately 
be the information needed to help clinicians better decide on a suitable therapeutic plan 
that includes both surgery and chemotherapy. 
 
Conclusion 310 
We showed the usefulness of the aCGH assessment in helping to differentiate 
between double primary lesions and metastatic lesions, in addition to improving the 
accuracy of the clinicopathological diagnosis. However, since the prognosis of the 
double primary group and metastasis group proved to be similar, this suggests that the 
small pm1 does not play an important role in determining the prognosis of patients with 315 
NSCLC. Furthermore, the better prognosis of pm1 group as compared to that in other T3 
group in N0 patients indicates that use of small pm1 as a T3 factor can result in an 
overestimation of the prognosis. Detailed investigations that specifically examine the size 
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and number of lesions that occur during intrapulmonary metastasis will need to be 
undertaken in order to definitively confirm the present findings.  320 
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Table 1: Clinicopathological factors of the analyzed patients 
MM pathology location size (mm) histology differentiation days outcome
1 : 62 F pm1 pm1 LUL (S1+2) 20 Adeno well 3394 alive
LUL (S1+2) 12 Adeno well
2 : 69 F pm1 pm1 LUL (S1+2) 15 Adeno well 1844 recurrence
LUL (S1+2) 10 Adeno well
3 : 76 M pm1 pm1 RML (S4) 60 Adeno well 218 recurrence
RML (S4) 9 Adeno well
4 : 79 F pm1 pm1 LUL (S1+2) 42 Adeno well 2195 alive
LUL (S1+2) 6 Adeno well
5 : 77 M primary pm1 RUL (S2) 45 Adeno well 281 recurrence
RUL (S3) 8 Adeno well
6 : 56 M primary pm1 RUL (S2) 17 Adeno moderately 2920 alive
RUL (S3) 19 Adeno moderately
7 : 65 M primary primary RML (S4) 15 Adeno moderately 267 recurrence
RUL (S2) 16 Adeno moderately
8 : 71 M primary primary LLL (S6) 120 Sq poorly 1254 alive
LUL (S1+2) 25 Sq moderately
9 : 72 F primary primary RLL (S6) 18 Adeno poorly 1825 alive
LLL (S8) 12 Adeno moderately
10 : 41 F primary primary RUL (S2) 32 Adeno well 1357 recurrence
LLL (S6) 24 Adeno moderately
11 : 57 F primary primary LLL (S6) 32 Adeno well 4126 alive
RLL (S3) 28 Adeno well
12 : 61 M primary primary RUL (S3) 33 Adeno moderately 297 recurrence
LUL (S1+2) 25 Adeno moderately
Abbreviations: MM: Martini and Melamed Criteria, DFS: disease free survival, LUL: left upper lobe, 
LLL: left lower lobe, RUL: right upper lobe, RML: right middle lobe, RLL; right lower lobe, 
Adeno: adenocarcinoma, Sq: squamous cell carcinoma.
dominant  diagnostic
factorNo. / age / sex
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Table 2: Primers used for polymerase chain reaction 
Primer (Primer length) Sequence
ex19 S-1 (28) ATCCCAGAAGGTGAGAAAGATAAAATTC
ex19 AS-1 (21) CCTGAGGTTCAGAGCCATGGA
ex19 HR-F (19) AAAATTCCCGTCGCTATCA
ex19 HR-R (18) AAGCAGAAACTCACATCG
ex21 f-s (21) CGCAGCATGTCAAGATCACAG
ex21 r-s (21) ACTTTGCCTCCTTCTGCATGG
ex21 HR-F (18) AGATCACAGATTTTGGGC
 5 
Arai J. et al. 
3 
 
Table 3: Clinicopathological assessment and molecular profile diagnosis results 
pathology MM concordance rate ( % ) diagnosis exon19 exon21 diagnosis days outcome
1 A / B pm1 pm1 2.6 primary ( + ) / ( + ) ( - ) / ( - ) metastasis 3394 alive
2 A / B pm1 pm1 67.3 metastasis ( + ) / ( + ) ( - ) / ( - ) metastasis 1844 recurrence
3 A / B pm1 pm1 61.6 metastasis ( - ) / ( - ) ( - ) / ( - ) equivocal 218 recurrence
4 A / B pm1 pm1 63 metastasis ( - ) / ( - ) ( + ) / ( + ) metastasis 2195 alive
5 A / B pm1 primary 87 metastasis ( - ) / ( - ) ( + ) / ( + ) metastasis 281 recurrence
6 A / B pm1 primary 51.2 metastasis ( - ) / ( - ) ( - ) / ( + ) primary 2920 alive
7 A / B primary primary 11 primary ( - ) / ( - ) ( - ) / ( + ) primary 267 recurrence
8 A / B primary primary 0.3 primary ( - ) / ( - ) ( - ) / ( - ) equivocal 1254 alive
9 A / B primary primary 10.9 primary ( - ) / ( - ) ( - ) / ( + ) primary 1825 alive
10A / B primary primary 23.2 primary ( - ) / ( - ) ( - ) / ( - ) equivocal 1357 recurrence
11 A / B primary primary 68.8 metastasis ( - ) / ( - ) ( - ) / ( - ) equivocal 4126 alive
12 A / B primary primary 3.4 primary ( - ) / ( + ) ( + ) / ( - ) accurate primary 297 recurrence
Abbreviations: A: primary tumor, B: secondary tumor, MM: Martini and Melamed Criteria, DFS: disease free survival.
Case
aCGH EGFR mutation DFSstatus
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Table 4: Characteristics of patients with synchronous double NSCLC (N0)  10 
double primary pm especiallypm1
N = 28 N = 38 p value N = 32 p value
sexa
male 20 27 23
female 8 11 0.97 9 0.98
agea
over 70 18 19 17
under 70 10 19 0.25 15 0.46
smokinga
+ 21 22 18
- 7 16 0.15 14 0.21
locationb
same 6 32
ipsilateral different 8 6
contralateral 14 0  <0.01
sizeb　(mm)
~30 20 22 18
31~70 7 11 9
71~ 2 5 0.24 5 0.33
histologyb
adeno 20 28 23
squamous 1 7 6
other 7 3 0.29 3 0.75
ly factora
( - ) 12 11 11
 ( + ) 12 25 20
unknown 4 2 0.13 1 0.36
v factora
( - ) 12 19 18
 ( + ) 13 16 13
unknown 3 3 0.63 1 0.52
p factora
( - ) 19 25 23
 ( + ) 9 12 9
unknown 0 1 0.98 0 0.79
a : Mann Whitney U test. b : Kruskal Wallis test.
Abbreviations: 
pm : intrapulmonary metastasis, pm1: intrapulmonary metastasis to the same lobe.  





Genomic profiles of 5 chromosome arms. A and B indicate the primary and secondary 
lesions, respectively. Case 2 profiles (2A and 2B) suggest a diagnosis of metastasis, 
while case 7 profiles (7A and 7B) suggest double primary lesions.  5 
Figure 2: 
a) The overall survival curves for the synchronous double NSCLC patients. 
b) The overall survival curves for pm1 and double primary NSCLC patients without 
lymph node metastasis. 
c) The disease free survival curves for pm1 and double primary NSCLC patients 10 
without lymph node metastasis. 
d) The overall survival curves for pm1 and T3 NSCLC patients without lymph node 











Supplemental Text I: Method used for DNA extraction from formalin-fixed, 
paraffin-embedded block tissue 
Five to ten slices of the microdissected tumor area that were 10 μm thick were 
removed from each formalin-fixed, paraffin-embedded block. These areas were 
identified using a hematoxylin and eosin stain. After removing the paraffin using 80% 
xylene, the deparaffinized tissue pieces were washed twice with absolute ethanol, and 
then spun down. After the pieces were dried, the pellet was resuspended in 360 μL of 
buffer ATL, incubated at 95°C for 15 minutes, followed by cooling of each sample to 
room temperature. After adding proteinase K to digest the samples, they were then 
incubated at 56°C in a rotation oven for three days, with periodic mixing and the 
addition of proteinase K every 24 hours. After three days, we added 400 μL of buffer 
AL (equal volume to sample suspension), followed by incubation at 70°C for 10 
 
 
minutes. Subsequently, we then added 400 μL of absolute ethanol, placed the samples 
into the spin column, followed by centrifugation at 8000 x g for 1 minute. The column 
was then washed twice with 500 μL of buffer AW1, centrifuged at 8000 x g for 1 
minute, washed once with buffer AW2, and then centrifuged once more time at 14,000 
x g for 3 minutes. Genomic DNA was eluted with 55 μL of buffer AE, and 200 μL of 
buffer TE. Extracted DNA was quantified on a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA).  
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Supplemental Text II: PCR-RFLP method used for the EGFR mutation search 
In order to examine the mutation of exon 19, we used ex19 S-1 for the forward primer 
and ex19 AS-1 for the reverse primer for the 1st PCR. We also used ex21 f-s for the 
forward primer and ex21 r-s for the reverse primer to examine the mutation of exon 21. 
DNA was amplified for 35 cycles at 94°C for 30 seconds, at 60°C for 30 seconds, and 5 
at 72°C for 30 seconds, followed by 5 minutes of extension at 72°C. For the 1st RFLP, 
the restriction enzyme MseI was used to digest the TTAA sequence in the wild-type 
genes, as this is frequently absent in exon 19 deletion mutants and results in the 
enrichment of deletion-type genes. In addition, the restriction enzyme MscI was used 
to digest the TGGCCA sequence in the wild-type genes, as the mutant type L858R in 10 
exon 21 is not digested due to the base substitution of T to G at the first base of 
TGGCCA. Because of this, there is enrichment of the L858R mutant. The 1st PCR 
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product obtained using these restriction enzymes was incubated at 37°C for 12 hours. 
For the 2nd PCR, we used ex19 HR-F for the forward primer and ex19 HR-R for the 
reverse primer in order to examine the mutation of exon 19. To examine the mutation 15 
of exon 21, we used ex21 HR-F for the forward primer and ex21 r-s for the reverse 
primer. The 1st RFLP product was amplified for 20 cycles at 94°C for 30 seconds, at 
60°C for 30 seconds, and at 72°C for 30 seconds, followed by 5 minutes of extension 
at 72°C for the 2nd PCR. For the 2nd RFLP, the restriction enzyme Sau96I was used to 
digest the GGNCC sequence. Since the wild-type is not digested, even partial digestion 20 
of the PCR product indicates the presence of a mutation in exon 21. The 1st PCR 
product obtained using these restriction enzymes was incubated at 37°C for 12 hours. 
However, this step was not required for the detection of the mutation in exon 19. After 
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the 2nd PCR or 2nd RFLP, the product was then analyzed on 6% or 8% Polyacrylamide 
Gel Electrophoresis. 25 













